Lv1
40 积分 2023-06-30 加入
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1天前
待确认
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
1天前
已完结
Phase III results for first-line treatment for metastatic colorectal cancer
1个月前
已完结
PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
1个月前
已完结
Immune evasion through mitochondrial transfer in the tumour microenvironment
2个月前
已完结
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
2个月前
已完结
Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer
2个月前
已完结
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
2个月前
已完结
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
3个月前
已完结
Tumor immune evasion arises through loss of TNF sensitivity
3个月前
已完结
皖公网安备34019202002308
